ESSA Pharma Inc

NASDAQ EPIX

Download Data

ESSA Pharma Inc Return on Net Investment (RONI) 3 year CAGR for the year ending September 19, 2024

ESSA Pharma Inc Return on Net Investment (RONI) 3 year CAGR is NA for the year ending September 19, 2024. Return on net investment measures the profitability of a company relative to its net investment, which includes total investments minus short-term investments and long-term debt. It is calculated by dividing the net income by the net investment. This ratio provides insights into the return generated for each unit of net investment made by the company. A higher return on net investment indicates better profitability and efficient utilization of the company's invested capital. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
NASDAQ: EPIX

ESSA Pharma Inc

CEO Dr. David Ross Parkinson M.D.
IPO Date July 9, 2015
Location Canada
Headquarters 999 West Broadway, Vancouver, BC, Canada, V5Z 1K5
Employees 50
Sector Healthcare
Industry Biotechnology
Description

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

StockViz Staff

September 19, 2024

Any question? Send us an email